Advertisement
LLY vs REGN
Which Stock Would AI Choose? Eli Lilly (LLY) vs. Regeneron (REGN) Stock Comparison
Key Takeaways
- LLY boasts a massive market cap of nearly $984 billion with explosive growth from GLP-1 drugs like Mounjaro and Zepbound, driving over 50% of revenues, though recent share pressure reflects sector cooling.
- REGN trades at a more attractive P/E of around 19 versus LLY's 45, supported by steady Dupixent expansions and Q4 earnings beats amid positive YTD momentum.
- Recent weeks show REGN gaining ~5% monthly with stronger relative stability (beta 0.41 vs. 0.39), contrasting LLY's ~1-5% pullback amid obesity market competition.
- Both benefit from pipeline wins—LLY in oral GLP-1s and Olumiant, REGN in Dupixent pediatric approvals—but REGN offers lower valuation for value-oriented traders.
- Biotech sector recovery favors growth leaders, yet REGN's consistent profitability edges in current risk-off sentiment.
Introduction
Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN) represent leading biotech forces in pharmaceuticals, with LLY dominating obesity and diabetes via GLP-1 therapies, and REGN excelling in immunology and ophthalmology through Dupixent and Eylea. This stock comparison analyzes their recent market positioning, performance metrics, and growth drivers amid a recovering large-cap pharma sector. Traders seeking high-growth exposure and investors prioritizing valuation trade-offs will find insights into relative momentum, pipeline catalysts, and sentiment shifts valuable for portfolio decisions in today's volatile biotech landscape.
LLY Overview and Recent Performance
Eli Lilly (LLY), a global pharmaceutical giant, focuses on neuroscience, oncology, immunology, and cardiometabolic diseases, with blockbuster GLP-1 drugs Mounjaro and Zepbound fueling rapid expansion. In 2025, these therapies generated $36.5 billion, comprising 56% of total revenues amid surging obesity demand. Recent market activity has seen shares cool from a 52-week high of $1,133.95, trading around $1,017 with YTD declines of about 5%, underperforming the S&P 500. Sentiment reflects competitive pressures from rivals like Novo Nordisk, yet positive catalysts include a $3.5 billion manufacturing investment, superior oral GLP-1 trial results over competitors, and CHMP recommendation for Olumiant expansion in alopecia areata. Technicals remain neutral, with support near $974, supporting long-term growth outlook despite near-term volatility.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN) specializes in biotechnology, leveraging its VelociSuite platform for antibody-based therapies targeting eye diseases, allergies, and cancer. Key products like Eylea and Dupixent (partnered with Sanofi) drove Q4 2025 revenues to $3.88 billion, beating estimates with EPS of $11.44. Shares have shown resilience, up ~5% over recent weeks to around $790 from a 52-week low of $476, with YTD gains of 2.5% and a monthly rise of 4.9%. Performance benefits from Dupixent's FDA approval for allergic fungal rhinosinusitis and CHMP nod for pediatric chronic spontaneous urticaria, expanding addressable markets. Analyst upgrades, like RBC's target hike to $765, bolster sentiment, though growth moderation pressures persist. Technical momentum leans bullish short-term, with dynamic supports holding firm.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of top-performing AI trading bots from its library of hundreds, which collectively trade thousands of tickers across diverse strategies like swing trading, day trading, and long-term holds. Only the most suitable bots for prevailing market conditions—based on metrics such as win rates often exceeding 60-80%, profit factors above 1.5, and consistent drawdown management—earn a spot in this dynamic trending section, currently featuring 25+ agents including signal providers and virtual portfolio managers. These bots vary in timeframe from intraday to multi-month, with performance stats highlighting annualized returns in the double digits for leaders. Traders can explore backtested results and live signals to align with styles fitting stocks like LLY or REGN. Visit the Trending AI Robots page to discover tools optimized for current volatility and sector trends.
Head-to-Head Comparison
LLY and REGN operate in overlapping biotech realms but diverge sharply in scale and focus: LLY's diversified pharma model emphasizes mass-market GLP-1 growth drivers, contrasting REGN's specialized biotech emphasis on high-margin antibodies like Dupixent. Recent momentum favors REGN with positive monthly gains and lower beta (0.41 vs. 0.39), while LLY contends with higher volatility from obesity competition. Valuation trade-offs highlight REGN's compelling P/E of 19 versus LLY's premium 45, reflecting LLY's superior revenue scale ($65B TTM vs. $14B). Risk factors include LLY's patent cliffs and pricing scrutiny, balanced by capacity expansions, against REGN's partnership dependencies and slower growth. Sector exposure aligns in immunology but LLY leads in cardiometabolics; market sentiment tilts toward REGN's stability in a cautious environment.
Tickeron AI Verdict
Tickeron’s AI currently favors REGN due to its superior recent momentum, attractive valuation, and pipeline stability amid sector headwinds. With consistent earnings beats, lower P/E relative to growth peers, and positive technical setups, REGN shows higher probability of near-term outperformance versus LLY's elevated premium and competitive pressures, though LLY retains upside from blockbuster catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LLY is a Buy and REGN is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LLY’s FA Score shows that 2 FA rating(s) are green whileREGN’s FA Score has 2 green FA rating(s).
- LLY’s FA Score: 2 green, 3 red.
- REGN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LLY’s TA Score shows that 7 TA indicator(s) are bullish while REGN’s TA Score has 3 bullish TA indicator(s).
- LLY’s TA Score: 7 bullish, 3 bearish.
- REGN’s TA Score: 3 bullish, 5 bearish.
Price Growth
LLY (@Pharmaceuticals: Major) experienced а -0.10% price change this week, while REGN (@Biotechnology) price change was +0.50% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.35%. For the same industry, the average monthly price growth was -1.12%, and the average quarterly price growth was +2.63%.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.17%. For the same industry, the average monthly price growth was +5.03%, and the average quarterly price growth was +8.71%.
Reported Earning Dates
LLY is expected to report earnings on Aug 05, 2026.
REGN is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.35% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+0.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| LLY | REGN | LLY / REGN | |
| Capitalization | 862B | 74.7B | 1,154% |
| EBITDA | 36.2B | 5.75B | 630% |
| Gain YTD | -9.871 | -7.546 | 131% |
| P/E Ratio | 34.35 | 17.40 | 197% |
| Revenue | 72.2B | 14.9B | 485% |
| Total Cash | 5.28B | 8.75B | 60% |
| Total Debt | 43.4B | 2.71B | 1,604% |
LLY | REGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 5 | 52 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 39 Fair valued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 18 | 78 | |
SMR RATING 1..100 | 13 | 58 | |
PRICE GROWTH RATING 1..100 | 55 | 57 | |
P/E GROWTH RATING 1..100 | 90 | 31 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for LLY (39) in the Pharmaceuticals Major industry. This means that REGN’s stock grew somewhat faster than LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (18) in the Pharmaceuticals Major industry is somewhat better than the same rating for REGN (78) in the Biotechnology industry. This means that LLY’s stock grew somewhat faster than REGN’s over the last 12 months.
LLY's SMR Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for REGN (58) in the Biotechnology industry. This means that LLY’s stock grew somewhat faster than REGN’s over the last 12 months.
LLY's Price Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as REGN (57) in the Biotechnology industry. This means that LLY’s stock grew similarly to REGN’s over the last 12 months.
REGN's P/E Growth Rating (31) in the Biotechnology industry is somewhat better than the same rating for LLY (90) in the Pharmaceuticals Major industry. This means that REGN’s stock grew somewhat faster than LLY’s over the last 12 months.
| LLY | REGN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 75% | 1 day ago 68% |
| Stochastic ODDS (%) | 1 day ago 46% | 1 day ago 69% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 64% |
| MACD ODDS (%) | 1 day ago 66% | 1 day ago 60% |
| TrendWeek ODDS (%) | 1 day ago 59% | 1 day ago 65% |
| TrendMonth ODDS (%) | 1 day ago 68% | 1 day ago 60% |
| Advances ODDS (%) | 8 days ago 70% | N/A |
| Declines ODDS (%) | 5 days ago 56% | 14 days ago 52% |
| BollingerBands ODDS (%) | 1 day ago 71% | 1 day ago 60% |
| Aroon ODDS (%) | 1 day ago 58% | 1 day ago 61% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SPY | 739.30 | 1.68 | +0.23% |
| State Street® SPDR® S&P 500® ETF | |||
| XEMD | 44.92 | 0.03 | +0.07% |
| BondBloxx JP Morgan USD EM 1-10 Yr BdETF | |||
| XDEC | 42.35 | 0.01 | +0.03% |
| FT Vest US Eq Enh & Mdt Bfr ETF Dec | |||
| CA | 24.99 | N/A | N/A |
| Xtrackers California Municipal Bond ETF | |||
| LFAI | 149.52 | N/A | N/A |
| LifeX 2050 Longevity Income ETF | |||
REGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with SMMT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then SMMT could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | -0.30% | ||
| SMMT - REGN | 43% Loosely correlated | +3.21% | ||
| ARQT - REGN | 39% Loosely correlated | +0.33% | ||
| IDYA - REGN | 35% Loosely correlated | -0.67% | ||
| GMAB - REGN | 34% Loosely correlated | -0.91% | ||
| INCY - REGN | 33% Poorly correlated | +1.81% | ||
More | ||||